Articles tagged "IVIG"

2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
S. C. Jordan¹, K. Kucher², M. Bagger², H. Hockey³, K. Wagner⁴, N. Ammerman¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Biometrics Matters Ltd, Hamilton, New Zealand, ⁴Novartis Institutes for BioMedical Research, Cambridge, MA
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…
2019 American Transplant Congress
Predictors of Response to Intravenous Immunoglobulin for Treatment of Polyoma Nephropathy
S. Sethi, A. Vo, A. Peng, R. Najjar, K. Lim, S. Jordan, E. Huang
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: BK nephropathy is an important cause of allograft dysfunction or loss. IVIg is hypothesized to be effective by providing passive immunity to BK virus…
2019 American Transplant Congress
Reduction of Circulating DSA: Does It Affect Histology?
M. Gupta¹, E. Edusei¹, S. Tsai², M. Magruder², J. Lee¹, J. Lee¹, C. Hartono¹, T. Muthukumar¹, M. Everly³, D. Dadhania¹
¹Nephrology, New York Presbyterian Weill Cornell, New York, NY, ²New York Presbyterian Weill Cornell, New York, NY, ³Terasaki Research Institute, Los Angeles, CA
*Purpose: De novo donor specific antibodies (dnDSA) are reported in 13-30% of kidney transplant recipients. dnDSA has been associated with antibody mediated rejection (AMR) and…
2019 American Transplant Congress
Desensitization Using Only Polyvalent Immunoglobulins (IVIG) for Kidney Transplantation with Living Donors (LD)
L. R. Ulisses, J. O. Paixão, P. S. Souza, G. Bezerra, H. Rodrigues, N. Panajatopoulos, F. J. De Paula, E. David-Neto, M. C. R Castro
Renal Transplant Service, Renal Transplant Service, Hospital das Clinicas and Laboratory of Immunology-LIM-19, Medical School of te University of São Paulo, São Paulo, Brazil, São Paulo, Brazil
*Purpose: HLA sensitization is a barrier for kidney transplantation. Sensitized patients stay longer on the waiting list and have higher mortality rate and complications while…
2019 American Transplant Congress
Sequential Dosing of Rituximab and IVIg for Desensitization of Highly-HLA Sensitized (HS) Patients Awaiting HLAi Kidney Transplantation
A. A. Vo, E. Huang, S. Williamsons, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, S. C. Jordan
Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Recent observations suggest that the use of IVIg + rituximab has a critical role in modifying allo-reactive B-cells prior to HLAi kidney transplantation, thus…
2019 American Transplant Congress
Pre-emptive Ivig For Dsa Positive Living Donor Kidney Transplant Recipients
B. Abdalla¹, D. Kellner², A. Diaz², Y. Zheng³, E. Reed⁴, Q. J. Zhang⁴
¹Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³UCLA Immunogenetics Center, Los Angeles, CA, ⁴Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Intravenous immunoglobulin (IVIG) is used in desensitization regimens to modulate anti-human leukocyte antigen (HLA) donor-specific antibody (DSA) to facilitate transplantation of sensitized patients, however,…
2019 American Transplant Congress
Effects of IVIG Therapy and FcγR Polymorphisms on BK Virus Nephropathy in Kidney Transplant Recipients
D. I. Min¹, Y. Chang², T. Shah³
¹Western Univ of Health Sciences, Los Angeles, CA, ²Mendez National Institute of Transplantation Foundation, Los Angeles, CA, ³St. Vincent Medical Center, Los Angeles, CA
*Purpose: BK Virus Nephropathy (BKVN) is a major complication in kidney transplant patients. Although standard treatment for BKVN is immunosuppression reduction and/or using leflunomide, studies…
2018 American Transplant Congress
Modified Protocol for ABO-Incompatible Living Donor Liver Transplantation with Rituximab and Intravenous Immunoglobulin without Plasma Exchange
B-.G. Na, E. Lee, S. Kim, S. Park.
Center for Liver Cancer, National Cancer Center, Il-san Donggu, Goyang, Republic of Korea.
Purpose: Since a variety of desensitization strategies including rituximab, intravenous immunoglobulin (IVIG), and plasma exchange (PE) have been introduced, the survival and outcomes of recipients…
2018 American Transplant Congress
Effect of HLA Antibodies on Graft Survival in Adult Live Donor Liver Transplantation
M. Simpson,¹ M. Akoad,¹ F. Gordon,¹ Y-.L. Cheah,¹ C. Simon,¹ J. Pomposelli,² E. Pomfret.²
¹Transplantation, Lahey Hospital & Medical Center, Burlington, MA; ²Transplantation, University of Colorado Medical Center, Aurora, CO.
The relevance of HLA antibodies in liver transplantation is currently being re-evaluated. While hyperacute rejections are not an issue, antibody effects on long-term outcomes are…
2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
A. Vo,¹ O. Aubert,² H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ J. Choi,¹ K. Lim,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research Center for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…